Home> Products> gliclazide

{ "products": [ { "_id": "665ef7cfea22b014e8aefff9", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLICLAGLAZE MR 30 ", "description": "GLICLAGLAZE MR 30 \ngliclazide sr (30 mg)\nIntroduction\nGLICLAGLAZE MR 30 is specifically formulated for individuals managing Type 2 diabetes. This medication utilizes a sustained release (SR) form of Gliclazide at a 30 mg dosage, focusing on providing a steady, controlled release of the drug to maintain optimal blood sugar levels throughout the day.\n\nHow It Works\n\nGliclazide SR (30 mg): Gliclazide is a sulfonylurea class drug that increases insulin secretion from the pancreas. Unlike standard formulations, the SR version releases the medication gradually, which helps to stabilize blood sugar levels and reduces the risk of severe fluctuations that can lead to hypoglycemia. This mechanism not only enhances the body’s natural insulin use but also supports overall vascular health, decreasing the risk of complications associated with diabetes, such as cardiovascular disease.\nBenefits\nGLICLAGLAZE MR 30 is an excellent choice for patients who require a mild enhancement in their insulin secretion with a lower risk of hypoglycemia. The SR formulation provides a more predictable pharmacokinetic profile, which is crucial for maintaining a stable glycemic control. This can significantly improve the quality of life for patients by reducing common side effects associated with blood sugar spikes and drops.\n\nDosage and Administration\n\nDosage: The dose of GLICLAGLAZE MR 30 should be adjusted based on the patient’s blood glucose response and previous treatment history. Regular monitoring of blood glucose and glycated hemoglobin (HbA1c) levels is recommended to ensure that the dosage is effective.\nAdministration: This medication should be taken with breakfast or the first main meal of the day. The tablet should be swallowed whole to maintain the integrity of the sustained release mechanism.\nSide Effects\nPossible side effects of GLICLAGLAZE MR 30 include gastrointestinal issues such as nausea and upset stomach. Due to its sulfonylurea component, there is a risk of hypoglycemia, although it is generally lower compared to other sulfonylureas due to the sustained release formulation.\n\nConclusion\nGLICLAGLAZE MR 30 is a practical and effective solution for managing Type 2 diabetes, especially suited for patients seeking a gentle modification in their diabetes treatment plan with sustained drug release. It simplifies diabetes management, potentially enhancing adherence and minimizing the risk of dosage-related complications. As with any medication, consultation with a healthcare provider is essential to tailor the treatment to individual needs and conditions.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/gliclaglaze-mr-30-133422", "price": 83.0, "discountamount": 24.9, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "day", "dose", "life", "body", "drops", "EMAIL", "Order", "upset", "tablet", "nausea", "stomach", "quality", "SR) form", "patients", "Benefits", "pancreas", "adherence", "integrity", "breakfast", "practical", "lower risk", "SR version", "medication", "conditions", "Conclusion", "individuals", "information", "sterisonline", "Introduction", "30 mg dosage", "consultation", "sterispharma", "hypoglycemia", "CALL/WHATSAPP", "Gliclazide SR", "HbA1c) levels", "SR formulation", "GLICLAGLAZE MR", "first main meal", "Type 2 diabetes", "mild enhancement", "individual needs", "excellent choice", "insulin secretion", "effective solution", "Regular monitoring", "blood sugar spikes", "healthcare provider", "diabetes management", "gentle modification", "other sulfonylureas", "common side effects", "glycated hemoglobin", "severe fluctuations", "natural insulin use", "Possible side effects", "standard formulations", "Administration Dosage", "sulfonylurea component", "sustained drug release", "blood glucose response", "cardiovascular disease", "diabetes treatment plan", "stable glycemic control", "gastrointestinal issues", "overall vascular health", "sulfonylurea class drug", "steady, controlled release", "optimal blood sugar levels", "previous treatment history", "sustained release mechanism", "dosage-related complications", "sustained release formulation", "predictable pharmacokinetic profile" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1291, "imageuri": "https://productimages.withfloats.com/actual/665ef7d253245b8b6b459895.png", "tileimageuri": "https://productimages.withfloats.com/tile/665ef7d253245b8b6b459895.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-04T11:17:35.736Z", "updatedon": "2024-06-04T11:17:35.736Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/gliclaglaze-mr-30-/1291", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLICLAGLAZE MR 30 ", "category": "DIABETIC RANGE", "tags": null, "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "665ef6a3161afa2274ff2581", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLICLAGLAZE MET ", "description": "GLICLAGLAZE MET \ngliclazide SR (60mg),Metformin SR (500 mg)\nIntroduction\nGLICLAGLAZE MET is an advanced formulation designed for the effective management of Type 2 diabetes. This oral medication combines sustained release (SR) forms of Gliclazide (60 mg) and Metformin (500 mg), offering controlled and consistent blood glucose control throughout the day.\n\nMechanism of Action\n\nGliclazide SR (60 mg): As a sulfonylurea drug, Gliclazide SR works by stimulating insulin secretion from the beta cells of the pancreas. The sustained release form provides a gradual increase in insulin levels, reducing the risk of sudden drops in blood sugar that can lead to hypoglycemia.\nMetformin SR (500 mg): Metformin SR decreases hepatic glucose production and increases insulin sensitivity in peripheral tissues, notably muscles. Its sustained release formulation ensures a steady effect on blood sugar levels, improving metabolic response without the peaks and troughs associated with immediate-release forms.\nBenefits\nGLICLAGLAZE MET is specifically tailored to provide a more stable and prolonged effect in controlling blood sugar, which can enhance patient compliance and comfort. The combination of Gliclazide SR and Metformin SR in one tablet simplifies the treatment regimen, potentially improving adherence and reducing the risk of missed doses.\n\nDosage and Administration\n\nDosage: The dosage of GLICLAGLAZE MET should be individualized based on the patient's current control and therapeutic response. It is crucial to monitor blood glucose regularly to adjust the dosage appropriately.\nAdministration: This medication should be taken with meals to minimize gastrointestinal side effects and improve the absorption of the drug.\nSide Effects\nWhile GLICLAGLAZE MET is generally well tolerated, some patients may experience side effects such as gastrointestinal discomfort, including nausea and diarrhea. The risk of hypoglycemia is present but is generally lower with the sustained release formulation.\n\nConclusion\nGLICLAGLAZE MET offers a balanced and effective approach to managing Type 2 diabetes by combining two proven diabetes medications in a sustained release form. This regimen not only aids in maintaining steady blood glucose levels but also supports overall diabetes management by enhancing patient adherence to treatment. Patients are encouraged to maintain a dialogue with their healthcare provider to optimize treatment outcomes and address any concerns during their treatment journey.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/gliclaglaze-met-133421\n\n\n\n\n\n", "price": 149.0, "discountamount": 44.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "mg", "day", "risk", "Order", "EMAIL", "peaks", "doses", "meals", "stable", "Action", "nausea", "muscles", "troughs", "Benefits", "pancreas", "diarrhea", "balanced", "dialogue", "concerns", "patients", "SR) forms", "Mechanism", "beta cells", "Conclusion", "one tablet", "controlled", "absorption", "combination", "information", "Metformin SR", "sudden drops", "hypoglycemia", "Introduction", "sterispharma", "sterisonline", "steady effect", "CALL/WHATSAPP", "gliclazide SR", "insulin levels", "oral medication", "current control", "Type 2 diabetes", "GLICLAGLAZE MET", "gradual increase", "prolonged effect", "insulin secretion", "patient adherence", "treatment journey", "treatment regimen", "sulfonylurea drug", "effective approach", "blood sugar levels", "metabolic response", "peripheral tissues", "patient compliance", "treatment outcomes", "healthcare provider", "insulin sensitivity", "advanced formulation", "effective management", "therapeutic response", "Administration Dosage", "sustained release form", "immediate-release forms", "hepatic glucose production", "overall diabetes management", "steady blood glucose levels", "gastrointestinal discomfort", "gastrointestinal side effects", "two proven diabetes medications", "consistent blood glucose control" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1289, "imageuri": "https://productimages.withfloats.com/actual/665ef6a67b1fc3f9dd48259d.png", "tileimageuri": "https://productimages.withfloats.com/tile/665ef6a67b1fc3f9dd48259d.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-04T11:12:35.652Z", "updatedon": "2024-06-04T11:12:35.652Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//gliclaglaze-met-/1289", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLICLAGLAZE MET ", "category": "DIABETIC RANGE", "tags": null, "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "665ef5bda743fd235821deeb", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLICLAGLAZE M 80 ", "description": "GLICLAGLAZE M 80 \ngliclazide (80mg),Metformin (500 mg)\nIntroduction\nGLICLAGLAZE M 80 is a specialized medication formulated for individuals diagnosed with Type 2 diabetes, aiming to enhance blood sugar regulation. This oral medication combines Gliclazide (80 mg) with Metformin (500 mg), two effective antidiabetic agents that provide a synergistic effect to control high blood sugar.\n\nMechanism of Action\n\nGliclazide (80 mg): Belonging to the sulfonylurea class, Gliclazide works by increasing insulin secretion from the pancreatic beta cells. It promotes a decrease in blood glucose levels and enhances the action of insulin in the body. Additionally, Gliclazide improves blood flow and has protective effects against the vascular complications of diabetes.\nMetformin (500 mg): Metformin reduces hepatic glucose production and improves insulin sensitivity by enhancing peripheral glucose uptake, particularly in muscle cells. This action helps lower blood glucose levels without the risk of inducing hypoglycemia and is associated with a potential reduction in body weight.\nBenefits\nGLICLAGLAZE M 80 offers a robust approach to managing Type 2 diabetes by targeting different aspects of the disease. The combination of Gliclazide and Metformin in this medication helps to control blood sugar more effectively than either component alone, potentially lowering the patient's risk of diabetes-related complications.\n\nDosage and Administration\n\nDosage: The starting dose should be adjusted based on the patient’s previous medication regimen, effectiveness, and tolerability. Dose adjustments should be made based on glycemic control, as assessed by regular monitoring of blood glucose levels.\nAdministration: It is recommended to take GLICLAGLAZE M 80 with meals to maximize drug absorption and minimize potential gastrointestinal side effects.\nSide Effects\nPotential side effects of GLICLAGLAZE M 80 include gastrointestinal symptoms like nausea and diarrhea, which usually improve over time. The risk of hypoglycemia exists but is moderated by the inclusion of Metformin.\n\nConclusion\nGLICLAGLAZE M 80 represents an effective treatment solution for managing Type 2 diabetes, combining two powerful antidiabetic agents to improve glycemic control and reduce the risk of diabetes complications. Patients should maintain regular consultations with their healthcare provider to tailor their treatment plan according to their specific needs, ensuring the best possible outcomes in diabetes management.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/gliclaglaze-m-80-133420\n\n\n\n\n\n", "price": 137.0, "discountamount": 41.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "risk", "time", "Order", "meals", "EMAIL", "nausea", "500 mg", "Action", "patient", "disease", "diarrhea", "Benefits", "decrease", "Mechanism", "Metformin", "component", "inclusion", "Conclusion", "blood flow", "gliclazide", "individuals", "information", "body weight", "combination", "Introduction", "muscle cells", "tolerability", "sterispharma", "hypoglycemia", "sterisonline", "starting dose", "effectiveness", "CALL/WHATSAPP", "GLICLAGLAZE M", "treatment plan", "specific needs", "Type 2 diabetes", "oral medication", "robust approach", "drug absorption", "high blood sugar", "Dose adjustments", "glycemic control", "different aspects", "insulin secretion", "regular monitoring", "sulfonylurea class", "synergistic effect", "protective effects", "healthcare provider", "insulin sensitivity", "potential reduction", "diabetes management", "blood glucose levels", "regular consultations", "pancreatic beta cells", "Administration Dosage", "best possible outcomes", "blood sugar regulation", "Potential side effects", "specialized medication", "diabetes complications", "vascular complications", "gastrointestinal symptoms", "peripheral glucose uptake", "hepatic glucose production", "previous medication regimen", "effective treatment solution", "diabetes-related complications", "two powerful antidiabetic agents", "two effective antidiabetic agents", "potential gastrointestinal side effects" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1287, "imageuri": "https://productimages.withfloats.com/actual/665ef5c0ca75628a5853ff45.png", "tileimageuri": "https://productimages.withfloats.com/tile/665ef5c0ca75628a5853ff45.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-04T11:08:45.584Z", "updatedon": "2024-06-04T11:08:45.584Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/gliclaglaze-m-80-/1287", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLICLAGLAZE M 80 ", "category": "DIABETIC RANGE", "tags": null, "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "665ef17474d94b15a06c31e2", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLICLAGLAZE M 40 ", "description": "GLICLAGLAZE M 40 \ngliclazide (40mg),Metformin (500 mg)\nIntroduction\nGLICLAGLAZE M 40 is a combination medication designed to manage blood sugar levels in individuals with Type 2 diabetes. This oral treatment integrates two potent antidiabetic agents: Gliclazide (40 mg) and Metformin (500 mg), each playing a crucial role in diabetes control.\n\nHow It Works\n\nGliclazide (40 mg): As a sulfonylurea, Gliclazide works by stimulating the release of insulin from the pancreatic beta cells. Insulin is the hormone responsible for reducing blood glucose levels. Gliclazide also enhances the sensitivity of peripheral tissues to insulin and reduces the likelihood of clot formation, which is a common complication in diabetes patients.\nMetformin (500 mg): Metformin acts primarily by reducing glucose production in the liver. It also improves insulin sensitivity, enhancing peripheral glucose uptake and utilization. Unlike many other antidiabetic medications, Metformin does not cause hypoglycemia (low blood sugar) and is often associated with weight loss.\nBenefits\nThe dual mechanism of GLICLAGLAZE M 40 offers a comprehensive approach to diabetes management by not only improving insulin production and sensitivity but also addressing the hepatic release of glucose. This combination reduces blood sugar levels effectively while minimizing the risk of side effects common to other diabetes treatments, such as hypoglycemia.\n\nUsage Guidelines\n\nDosage: Typically, the initial dosage is guided by the patient’s current treatment regimen, effectiveness, and tolerability. Adjustment in dosage should be made based on the patient’s blood glucose response, under the supervision of a healthcare provider.\nAdministration: GLICLAGLAZE M 40 should be taken with meals to reduce gastrointestinal side effects and to enhance absorption.\nSide Effects\nWhile GLICLAGLAZE M 40 is generally well-tolerated, it may cause some side effects. Common ones include gastrointestinal disturbances such as nausea and diarrhea, which are often transient. Hypoglycemia may occur, but it is less frequent due to the mitigating action of Metformin.\n\nConclusion\nGLICLAGLAZE M 40 is a cornerstone in the pharmacological treatment of Type 2 diabetes, offering benefits derived from the combined effects of Gliclazide and Metformin. It is essential for patients to follow their healthcare provider’s instructions and to maintain regular check-ups to optimize treatment outcomes and prevent complications. This medication enables patients to manage their diabetes more effectively and improve their quality of life.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/gliclaglaze-m-40-133419\n\n\n\n\n\n\n\n", "price": 149.0, "discountamount": 44.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "life", "risk", "liver", "meals", "40 mg", "Order", "EMAIL", "500 mg", "nausea", "quality", "hormone", "diarrhea", "Benefits", "Metformin", "gliclazide", "Adjustment", "likelihood", "Conclusion", "absorption", "utilization", "cornerstone", "information", "supervision", "individuals", "weight loss", "sulfonylurea", "hypoglycemia", "Introduction", "tolerability", "sterisonline", "instructions", "sterispharma", "crucial role", "complications", "GLICLAGLAZE M", "CALL/WHATSAPP", "effectiveness", "oral treatment", "dual mechanism", "clot formation", "Administration", "initial dosage", "Type 2 diabetes", "hepatic release", "low blood sugar", "diabetes control", "combined effects", "mitigating action", "diabetes patients", "regular check-ups", "blood sugar levels", "treatment outcomes", "peripheral tissues", "glucose production", "insulin production", "diabetes management", "insulin sensitivity", "common complication", "healthcare provider", "blood glucose levels", "pancreatic beta cells", "combination medication", "blood glucose response", "comprehensive approach", "Usage Guidelines Dosage", "pharmacological treatment", "peripheral glucose uptake", "current treatment regimen", "other diabetes treatments", "gastrointestinal disturbances", "gastrointestinal side effects", "two potent antidiabetic agents", "many other antidiabetic medications" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1284, "imageuri": "https://productimages.withfloats.com/actual/665ef175c06ee12d88caa810.png", "tileimageuri": "https://productimages.withfloats.com/tile/665ef175c06ee12d88caa810.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-04T10:50:28.577Z", "updatedon": "2024-06-04T10:50:28.577Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/gliclaglaze-m-40-/1284", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLICLAGLAZE M 40 ", "category": "DIABETIC RANGE", "tags": null, "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6943af86161ad9de85f42b10", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Imatinib IP 400mg", "description": "IMATIFLOW 400, containing Imatinib IP 400mg, represents a breakthrough in targeted cancer therapy, offering patients a precise weapon against specific malignancies. This oral medication belongs to the class of tyrosine kinase inhibitors, revolutionizing treatment for conditions once deemed challenging to manage. By blocking abnormal proteins that fuel cancer cell growth, IMATIFLOW 400 helps restore normal cellular function and improves quality of life for many users.​\n\nProduct Overview\nIMATIFLOW 400 is a branded formulation of Imatinib mesylate 400mg, produced to high pharmaceutical standards for consistent efficacy and bioavailability. Each tablet delivers the active ingredient in a film-coated form, designed for once-daily administration with food to enhance absorption and minimize gastrointestinal upset. Developed for adult patients, it targets cancers driven by dysregulated tyrosine kinases like BCR-ABL, c-KIT, and PDGFR, making it a cornerstone in modern oncology protocols.​\n\nThe medication's mechanism hinges on competitive inhibition at the ATP-binding site of these kinases, halting downstream signaling pathways that promote uncontrolled proliferation, survival, and metastasis of malignant cells. Unlike traditional chemotherapy, which broadly attacks dividing cells, IMATIFLOW 400 spares most healthy tissues, leading to a more favorable safety profile. Clinical data from pivotal trials underscore its role as first-line therapy, with high response rates observed within months of initiation.​\n\nPrimary Uses\nIMATIFLOW 400 excels in treating chronic myeloid leukemia (CML), particularly in the chronic phase where it induces deep molecular responses in over 80% of patients. It suppresses the Philadelphia chromosome-positive cells hallmark of CML by inhibiting the BCR-ABL fusion protein, dramatically extending progression-free survival. For newly diagnosed patients, standard dosing starts at 400mg daily, often achieving complete cytogenetic remission.​\n\nIn gastrointestinal stromal tumors (GIST), IMATIFLOW 400 targets KIT or PDGFRA mutations, shrinking unresectable tumors and delaying progression in advanced cases. The recommended dose remains 400mg once daily, with potential escalation to 600-800mg for resistant strains, as per oncology guidelines. It also finds application in dermatofibrosarcoma protuberans (DFSP), aggressive systemic mastocytosis, and certain myelodysplastic syndromes, broadening its utility in precision medicine.​\n\nHealthcare providers monitor response via PCR for BCR-ABL transcripts in CML or imaging for GIST, adjusting therapy based on milestones like major molecular response. Patients with Ph+ acute lymphoblastic leukemia (ALL) may receive it adjunctively, enhancing outcomes when combined with chemotherapy. Overall, IMATIFLOW 400 transforms these diseases from fatal to chronically manageable.​\n\nKey Benefits\nOne standout benefit of IMATIFLOW 400 is its oral convenience, eliminating the need for frequent hospital visits associated with infusions. Response rates exceed 90% in early CML, with many patients achieving treatment-free remission after sustained deep responses, a paradigm shift from interferon-era therapies.​\n\nTumor control in GIST prevents life-threatening complications like bowel obstruction, improving survival from months to years. Its specificity reduces severe toxicities, allowing patients to maintain daily activities, work, and social engagements with minimal disruption. Long-term studies report 10-year survival rates above 80% in CML, underscoring durable efficacy.​\n\nAdditional advantages include cost-effectiveness over biologics and compatibility with supportive care like hydroxyurea for cytoreduction. Fluid retention, while common, responds well to diuretics, preserving cardiac function. For Indian patients, accessible pricing via brands like IMATIFLOW 400 supports equitable care in resource-limited settings.​\n\nPotential Side Effects\nWhile generally well-tolerated, IMATIFLOW 400 can cause edema (swelling in legs or face) in up to 70% of users, managed by dose reduction or supportive measures. Gastrointestinal issues like nausea, vomiting, and diarrhea affect 40-50%, often resolving with antiemetics and dietary adjustments.​\n\nMusculoskeletal pain, cramps, and fatigue occur frequently, alongside rash and abdominal discomfort. Hematologic effects include neutropenia or thrombocytopenia, necessitating regular blood counts. Rare but serious risks involve liver enzyme elevation, heart failure, or hemorrhage; prompt reporting of symptoms like shortness of breath or yellowing skin is crucial.​\n\nAvoid grapefruit juice, as it elevates drug levels, and inform doctors of concurrent medications like CYP3A4 inhibitors. Pregnancy category D status advises contraception, with monitoring for growth retardation in exposed fetuses. Dizziness may impair driving, so caution is essential during initial weeks.​\n\nDosage and Administration Guidelines\nSwallow IMATIFLOW 400 whole with a meal and full glass of water to optimize pharmacokinetics and reduce esophageal irritation. The standard adult dose for CML chronic phase is 400mg daily; for accelerated phase or blast crisis, 600mg. GIST dosing mirrors 400mg, titrated based on tolerance and response.​\n\nRenal or hepatic impairment requires dose adjustments—reduce to 300-400mg in moderate cases. Do not crush or chew tablets. Missed doses should be taken promptly unless near the next, avoiding doubles. Long-term use demands quarterly monitoring of CBC, liver function, and ECG.​\n\nPrecautions and Interactions\nPatients with a cardiac history need baseline echocardiograms, as QT prolongation or effusion risks exist. Drug interactions abound: St. John's wort induces metabolism, reducing efficacy; ketoconazole boosts levels. Vaccines, especially live ones, are contraindicated during therapy.​\n\nRegular dermatologic checks mitigate skin cancer risk from prolonged use. Hydration combats fluid retention, and low-salt diets aid management. Steris Healthcare emphasizes patient education via counseling on adherence for optimal outcomes.​\n\nConclusion\nIMATIFLOW 400 (Imatinib IP 400mg) stands as a testament to targeted therapy's power, offering robust control over CML, GIST, and related cancers with a balance of efficacy and manageability. Its benefits in prolonging life and enhancing daily functioning far outweigh transient side effects for most when monitored diligently. Consult oncologists for personalized plans, ensuring this innovative treatment maximizes hope and health in the fight against cancer.", "price": 1827.0, "discountamount": 540.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2249, "imageuri": "https://productimages.withfloats.com/actual/6943b026ca1b0dcfc6c37820.png", "tileimageuri": "https://productimages.withfloats.com/tile/6943b026ca1b0dcfc6c37820.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-18T07:38:46.766Z", "updatedon": "2025-12-18T07:41:25.851Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/imatinib-ip-400mg/2249", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "IMATIFLOW 400", "category": "NEPHROLOGYRANGE", "tags": [ "Imatinib IP 400mg", "offering robust control over CML.", "related cancers with a balance of efficacy and manageability.", "innovative treatment maximizes hope and health in the fight against cancer.", "cancer therapy.", "fuel cancer cell growth.", "chemotherapy." ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "694004d8504825bb23fa3c1f", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Terbinafine and Itraconazole Tablets 250/100 mg", "description": "CONARIS T100 is a potent antifungal medication formulated with Terbinafine 250 mg and Itraconazole 100 mg. This combination tablet is designed to treat a wide range of fungal infections affecting the skin, nails, and other body parts. Terbinafine and Itraconazole work synergistically to eliminate fungi effectively by targeting their cell membranes and inhibiting growth, providing faster relief from symptoms such as itching, redness, scaling, and discomfort.\n\nFungal infections are common in humid climates and among individuals with compromised immunity, and medications like CONARIS T100 are essential for managing stubborn and recurrent infections. This combination therapy is often prescribed by dermatologists and healthcare professionals for moderate to severe fungal conditions.\n\nUses\n\nCONARIS T100 is used in the treatment of several fungal infections, including:\n\nDermatophytosis (Ringworm): Effective against infections of the skin, hair, and nails caused by dermatophytes.\n\nOnychomycosis (Nail Fungus): Helps in treating fungal infections of fingernails and toenails.\n\nTinea Infections: Treats tinea corporis, tinea cruris, and tinea pedis (athlete’s foot).\n\nCandidiasis: Useful in managing Candida infections affecting the skin and mucous membranes.\n\nRecurrent or Resistant Fungal Infections: Provides stronger antifungal action in cases not responsive to monotherapy.\n\nBenefits\n1. Broad-Spectrum Antifungal Action\n\nThe combination of Terbinafine and Itraconazole ensures effective activity against a wide variety of fungal species, including dermatophytes and yeasts.\n\n2. Faster Symptom Relief\n\nBy targeting fungi at multiple levels, CONARIS T100 helps relieve itching, redness, scaling, and discomfort more quickly than single-agent therapy.\n\n3. Treats Nail and Skin Infections\n\nTerbinafine penetrates nails effectively, while Itraconazole enhances the antifungal spectrum, making the combination ideal for nail and skin fungal infections.\n\n4. Reduces Recurrence\n\nCombination therapy decreases the risk of fungal infections returning by ensuring complete eradication of the pathogen.\n\n5. Convenient Dosage Form\n\nAvailable as an oral tablet, making it easy to administer and suitable for long-term treatment if prescribed.\n\nDosage\n\nAdults: Usually, one tablet of CONARIS T100 daily, preferably after meals, or as directed by a healthcare professional.\n\nTreatment Duration: Varies depending on the type and severity of infection; may range from 2 to 12 weeks for skin infections and longer for nail infections.\n\nImportant: Do not self-adjust dosage or stop treatment prematurely, as incomplete therapy can lead to recurrence or resistance.\n\nSide Effects\n\nCONARIS T100 is generally well tolerated when used as prescribed. Mild side effects may include:\n\nNausea or vomiting\n\nStomach upset or diarrhea\n\nHeadache\n\nDizziness\n\nSerious Side Effects (Rare)\n\nLiver enzyme elevation (monitoring recommended for long-term use)\n\nAllergic reactions such as rash, itching, or swelling\n\nSevere gastrointestinal discomfort\n\nConsult a healthcare provider immediately if you experience jaundice, persistent fatigue, or severe allergic reactions.\n\nPrecautions and Warning\n\nPregnancy and Breastfeeding: Use only if prescribed by a doctor; safety during pregnancy is not fully established.\n\nLiver or Kidney Disorders: Dose adjustment or close monitoring may be required.\n\nDrug Interactions: Inform your doctor about all medications, especially antifungals, statins, or anticoagulants.\n\nAvoid Self-Medication: Fungal infections may mimic other skin conditions, so proper diagnosis is essential.\n\nAlcohol Consumption: Avoid alcohol as it may increase liver toxicity risk.\n\nStorage: Store in a cool, dry place away from direct sunlight and out of children’s reach.\n\nConclusion\n\nCONARIS T100, containing Terbinafine 250 mg and Itraconazole 100 mg, is a reliable and effective treatment for a wide spectrum of fungal infections, including skin, nail, and mucosal infections. Its dual-action antifungal mechanism provides faster symptom relief, reduces recurrence, and improves overall patient outcomes.\n\nWhen used under medical supervision and following prescribed dosage, CONARIS T100 offers a safe and convenient option for managing both common and stubborn fungal infections, ensuring better skin and nail health and enhanced quality of life.", "price": 184.0, "discountamount": 55.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2248, "imageuri": "https://productimages.withfloats.com/actual/694004da351fe1d6b98476e6.png", "tileimageuri": "https://productimages.withfloats.com/tile/694004da351fe1d6b98476e6.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-15T12:53:44.573Z", "updatedon": "2025-12-16T05:44:32.639Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/terbinafine-and-itraconazole-tablets-250-100-mg/2248", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "CONARIS T100", "category": "DERMATALOGY", "tags": [ "terbinafine and itraconazole tablets", "terbinafine and itraconazole together", "terbinafine and itraconazole tablets uses", "terbinafine and itraconazole for nail fungus" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "69400387893a9153e4bd58a8", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Terbinafine and Itraconazole Tablets 250/200mg", "description": "CONARIS T200 is a potent antifungal combination tablet containing Terbinafine 250 mg and Itraconazole 200 mg, formulated to provide effective treatment for various fungal infections. Fungal infections of the skin, nails, and hair are common in India due to the hot and humid climate. These infections can cause itching, redness, scaling, and discomfort, affecting daily life and confidence.\n\nBy combining two powerful antifungal agents, CONARIS T200 targets fungal infections effectively, providing faster relief and improved recovery compared to monotherapy. Terbinafine works by inhibiting fungal cell growth, while Itraconazole disrupts fungal cell membrane formation, resulting in a comprehensive antifungal effect.\n\nUses\n\nCONARIS T200 is primarily prescribed for the management of:\n\nDermatophytosis (Ringworm, Tinea Infections)\nTreats fungal infections affecting skin, nails, and scalp.\n\nOnychomycosis (Fungal Nail Infection)\nHelps in eliminating nail fungus and promotes healthy nail growth.\n\nCandidiasis (Yeast Infections)\nEffective against mucocutaneous and superficial candidal infections.\n\nOther Superficial Fungal Infections\nUseful in treating skin infections caused by dermatophytes, yeasts, and other fungi.\n\nThis combination is particularly beneficial for chronic, resistant, or recurrent fungal infections.\n\nBenefits\n1. Broad-Spectrum Antifungal Activity\n\nThe dual action of Terbinafine and Itraconazole ensures effectiveness against a wide range of fungi, providing comprehensive treatment.\n\n2. Faster Symptom Relief\n\nPatients experience reduced itching, redness, scaling, and discomfort sooner than with single antifungal therapy.\n\n3. Promotes Healing\n\nSupports the restoration of healthy skin and nails, improving appearance and comfort.\n\n4. Reduces Recurrence\n\nThe combination therapy helps prevent fungal infections from returning, especially in chronic or resistant cases.\n\n5. Convenient Oral Administration\n\nOnce- or twice-daily tablet dosing improves patient compliance compared to topical treatments.\n\n6. Suitable for Adults\n\nFormulated for adult patients suffering from persistent fungal infections that require systemic therapy.\n\nDosage\n\nThe recommended dose of CONARIS T200 is usually one tablet once daily, or as directed by a physician.\n\nDuration of therapy depends on the type and severity of infection:\n\nSkin infections: Typically 2–4 weeks\n\nNail infections: May require 6–12 weeks or longer for full recovery\n\nImportant Instructions:\n\nSwallow the tablet whole with water.\n\nTake the medicine after food to reduce stomach upset.\n\nDo not skip doses and complete the full course even if symptoms improve.\n\nAlways follow the prescribing doctor’s instructions to ensure optimal results.\n\nSide Effects\n\nCONARIS T200 is generally well-tolerated, but some patients may experience mild side effects:\n\nNausea and vomiting\n\nStomach discomfort or indigestion\n\nHeadache\n\nDizziness\n\nSerious but Rare Side Effects\n\nLiver function disturbances\n\nAllergic reactions such as rash or swelling\n\nSevere gastrointestinal discomfort\n\nIf any unusual or severe symptoms appear, consult a healthcare professional immediately.\n\nPrecautions and Warning\n\nLiver and Kidney Disorders: Use with caution; liver function tests may be recommended during therapy.\n\nPregnancy and Breastfeeding: Consult your doctor before use; safety has not been fully established.\n\nDrug Interactions: Inform your doctor about other medications, particularly antacids, anticoagulants, or statins.\n\nAllergy: Avoid if allergic to Terbinafine, Itraconazole, or any other ingredient in the tablet.\n\nAlcohol Consumption: Limit alcohol intake, as it may increase the risk of liver-related side effects.\n\nConclusion\n\nCONARIS T200 (Terbinafine 250 mg + Itraconazole 200 mg) is an effective and trusted antifungal combination for the treatment of a variety of superficial and chronic fungal infections. By targeting fungi through dual mechanisms, it provides faster relief, promotes healing, and helps prevent recurrence. With proper dosing, adherence to medical advice, and monitoring for side effects, CONARIS T200 offers a comprehensive solution for adults dealing with persistent fungal infections, helping restore healthy skin, nails, and overall comfort.", "price": 204.0, "discountamount": 61.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2247, "imageuri": "https://productimages.withfloats.com/actual/69400389f34633ae3de3f8f4.png", "tileimageuri": "https://productimages.withfloats.com/tile/69400389f34633ae3de3f8f4.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-15T12:48:07.707Z", "updatedon": "2025-12-16T05:48:08.096Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/terbinafine-and-itraconazole-tablets-250-200mg/2247", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "CONARIS T200", "category": "DERMATALOGY", "tags": [ "terbinafine and itraconazole tablets", "terbinafine and itraconazole", "terbinafine and itraconazole combination", "terbinafine and itraconazole together", "Fungal infections of the skin", "helping restore healthy skin" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "69400227de5d3e57a9340a50", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Nebivolol and s-amlodipine Tablets 5/2.5 mg", "description": "NEBIVALVE AM is a combination tablet containing Nebivolol and S-Amlodipine, designed to provide effective management of hypertension (high blood pressure). Hypertension is a leading risk factor for cardiovascular diseases in India, including heart attacks, strokes, and kidney complications.\n\nThis dual-action formulation combines the benefits of Nebivolol, a cardio-selective beta-blocker, with S-Amlodipine, a calcium channel blocker, providing comprehensive blood pressure control. The combination helps relax blood vessels, improve blood flow, and reduce cardiac workload, offering a convenient and effective option for patients requiring combination therapy.\n\nUses\n\nNEBIVALVE AM is primarily prescribed for:\n\nEssential Hypertension\nLowers elevated blood pressure to reduce the risk of cardiovascular complications.\n\nCardiovascular Risk Reduction\nHelps in preventing heart attacks, strokes, and heart failure in high-risk patients.\n\nManagement of Stable Angina\nBy reducing cardiac workload and improving oxygen supply to the heart.\n\nCombination Therapy in Resistant Hypertension\nSuitable for patients who do not achieve target blood pressure with single-drug therapy.\n\nBenefits\n1. Dual Mechanism of Action\n\nNebivolol: Blocks beta-1 adrenergic receptors in the heart, reducing heart rate and cardiac output. It also promotes nitric oxide release, helping dilate blood vessels.\n\nS-Amlodipine: Relaxes vascular smooth muscles by blocking calcium channels, improving blood flow and reducing blood pressure.\n\n2. Effective Blood Pressure Control\n\nThe combination provides better blood pressure reduction compared to either drug alone, helping patients achieve their target levels faster.\n\n3. Cardiovascular Protection\n\nReduces strain on the heart, lowers risk of stroke, and supports overall heart health.\n\n4. Once-Daily Convenience\n\nThe tablet can be taken once daily, enhancing patient adherence to therapy.\n\n5. Well-Tolerated Formulation\n\nBoth Nebivolol and S-Amlodipine are generally well tolerated, minimizing side effects when used as prescribed.\n\nDosage\n\nTypical Dose: One tablet of NEBIVALVE AM once daily, preferably at the same time each day.\n\nAdministration: Swallow the tablet whole with water. Do not crush or chew.\n\nIndividualization: The dose may be adjusted by the physician based on blood pressure response and patient tolerability.\n\nLifestyle Measures: Continue dietary modifications, regular exercise, and salt restriction alongside medication for optimal results.\n\nImportant: Do not stop the medication abruptly without consulting your doctor, as sudden withdrawal may worsen blood pressure control or cardiac function.\n\nSide Effects\n\nNEBIVALVE AM is generally well tolerated, but some patients may experience mild side effects, including:\n\nDizziness or lightheadedness\n\nFatigue or weakness\n\nHeadache\n\nFlushing or swelling of ankles (edema)\n\nMild gastrointestinal discomfort\n\nRare but Serious Side Effects\n\nSlow heart rate (bradycardia)\n\nSevere hypotension (low blood pressure)\n\nWorsening of heart failure in susceptible patients\n\nAllergic reactions such as rash or swelling\n\nSeek immediate medical attention if severe symptoms such as fainting, chest pain, or shortness of breath occur.\n\nPrecautions and Warning\n\nPregnancy and Breastfeeding: Use only if clearly indicated and prescribed by a doctor.\n\nHeart Conditions: Inform your doctor if you have heart failure, arrhythmia, or recent heart attack.\n\nKidney or Liver Impairment: Dose adjustment may be necessary.\n\nDiabetes: Nebivolol may mask symptoms of low blood sugar; monitor blood glucose closely.\n\nDrug Interactions: Notify your doctor about all medications, especially other blood pressure drugs, anti-arrhythmics, or diuretics.\n\nAvoid Alcohol: Alcohol may increase the risk of hypotension or dizziness.\n\nRegular Monitoring: Blood pressure and heart rate should be monitored periodically during therapy.\n\nConclusion\n\nNEBIVALVE AM (Nebivolol and S-Amlodipine Tablets) is a safe and effective combination therapy for managing hypertension and reducing cardiovascular risks. By combining Nebivolol’s beta-blocking and vasodilatory effects with S-Amlodipine’s calcium channel blocking action, it provides superior blood pressure control and cardiovascular protection.", "price": 210.0, "discountamount": 63.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2246, "imageuri": "https://productimages.withfloats.com/actual/69400229d51eeda87e74dba0.png", "tileimageuri": "https://productimages.withfloats.com/tile/69400229d51eeda87e74dba0.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-15T12:42:15.327Z", "updatedon": "2025-12-16T05:52:43.351Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/nebivolol-and-s-amlodipine-tablets-5-2-5-mg/2246", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "NEBIVALVE AM", "category": "CARDIOLOGY", "tags": [ "nebivolol and s-amlodipine tablets", "nebivolol and s-amlodipine tablets uses", "nebivolol and s-amlodipine tablets uses in hindi", "nebivolol", "s-amlodipine tablets", "hypertension (high blood pressure)", "heart attacks", "strokes", "kidney complications", "blood pressure contro", "helps relax blood vessels", "improve blood flow" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "693fe9932d306b0fd119914b", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Povidone Iodine BP 2% w/v", "description": "PROVAMED 2% is an effective antiseptic mouthwash formulated with Povidone Iodine BP 2% w/v, designed to maintain oral hygiene and prevent infections. Povidone iodine is a broad-spectrum antimicrobial agent, active against bacteria, viruses, and fungi. PROVAMED 2% is widely recommended by dentists and ENT specialists for its ability to control oral microbial growth, relieve minor irritations, and support recovery after dental procedures. It is a trusted solution for both preventive and therapeutic oral care.\n\nUses\n\nPROVAMED 2% mouthwash is suitable for a variety of oral health needs, including:\n\nPrevention of Oral Infections: Reduces bacterial and fungal growth in the mouth.\n\nGingivitis and Periodontitis: Helps manage gum inflammation and microbial load.\n\nPost-Dental Procedures: Recommended after tooth extraction, scaling, or minor oral surgeries.\n\nSore Throat and Pharyngitis: Provides relief from mild throat infections.\n\nMouth Ulcers and Stomatitis: Supports faster healing by controlling microbial activity.\n\nDaily Oral Hygiene: Helps maintain fresh breath and healthy gums.\n\nBenefits\n1. Broad-Spectrum Antimicrobial Action\n\nPROVAMED 2% is effective against bacteria, viruses, and fungi, making it a reliable preventive and therapeutic mouthwash.\n\n2. Promotes Oral Healing\n\nSpeeds up recovery from minor oral injuries, mouth ulcers, and post-procedure inflammation.\n\n3. Reduces Discomfort\n\nHelps relieve soreness, redness, and irritation in gums and oral tissues.\n\n4. Convenient and Easy to Use\n\nThe ready-to-use liquid formulation allows for simple oral rinsing.\n\n5. Safe and Trusted\n\nPovidone iodine is clinically proven, widely used, and recognized for its safety when used as directed.\n\nDosage\n\nAdults and Children above 12 years: Rinse with 10–15 ml of PROVAMED 2% for 30–60 seconds, 2–3 times daily.\n\nChildren under 12 years: Use only under medical supervision with a reduced amount.\n\nPost-Dental Procedures: Follow the dentist’s instructions regarding duration and frequency.\n\nImportant: Spit out the mouthwash after use; do not swallow.\n\nSide Effects\n\nPROVAMED 2% is generally well tolerated. Possible side effects may include:\n\nTemporary staining of teeth or tongue\n\nMild burning sensation in the mouth\n\nAltered taste perception\n\nRare side effects include:\n\nAllergic reactions such as rash, itching, or swelling\n\nIncreased soreness if overused\n\nIn case of severe reactions, discontinue use and consult a healthcare professional.\n\nPrecautions and Warning\n\nDo Not Swallow: Intended for oral rinsing only.\n\nAllergy Alert: Avoid if allergic to iodine or povidone iodine.\n\nPregnancy and Breastfeeding: Use only under medical supervision.\n\nMedical Conditions: Exercise caution in patients with thyroid disorders, kidney disease, or iodine sensitivity.\n\nAvoid Eye Contact: Rinse thoroughly if contact occurs.\n\nStorage: Keep in a cool, dry place away from sunlight and out of children’s reach.\n\nConclusion\n\nPROVAMED 2% (Povidone Iodine Mouthwash BP 2% w/v) is a safe and effective solution for maintaining oral hygiene, preventing infections, and supporting recovery from minor oral ailments or dental procedures. Its broad-spectrum antimicrobial properties, ease of use, and proven safety make it a trusted choice for both preventive care and therapeutic use. By incorporating PROVAMED 2% into daily oral hygiene routines or using it as directed post-dental procedures, patients can maintain healthier gums, reduce microbial growth, and prevent oral infections effectively.", "price": 205.0, "discountamount": 61.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2245, "imageuri": "https://productimages.withfloats.com/actual/693fe996f663c8627e8ac951.png", "tileimageuri": "https://productimages.withfloats.com/tile/693fe996f663c8627e8ac951.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-15T10:57:23.837Z", "updatedon": "2025-12-16T05:55:54.82Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/povidone-iodine-bp-2-w-v/2245", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "PROVAMED 2% MOUTHWASH", "category": "DENTAL", "tags": [ "povidone iodine mouthwash", "povidone iodine mouthwash uses", "povidone iodine mouthwash bp 2 w/v uses", "povidone iodine mouthwash bp 2 w/v", "control oral microbial growth", "Reduces bacterial and fungal growth in the mouth", "Helps manage gum inflammation and microbial load." ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }